MSI1 and glioblastoma: To determine the efficiency of the decoy peptides on competing AGO2 interaction with endogenous MSI1, FAM was used to label the HIV-TAT-conjugated (TAT-FAM) peptides that were then utilized to assess the uptake rate by measuring concentration of decoy peptide at half-maximal response (EC50) in GBM cells.